First successful trial in heart failure with preserved ejection fraction
According to the trial results, Jardiance reduces the risk of death or hospitalisation due to heart failure for diabetic and non-diabetic patients with HFpEF.
Cardiovascular
FDA grants approval to Boehringer-Lilly’s Jardiance to treat HFrEF
The approval is based on results from the global Phase III EMPEROR-Reduced trial in 3,730...
Hypertension: study suggests ARBs should be used before ACE inhibitors
Researchers found that while ACE inhibitors and ARBs are similarly beneficial, the latter carry a...
Exercise should be first line of defence against elevated blood pressure
Healthcare experts have recommended exercise as a first-line treatment for mild to moderate-risk blood pressure...
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
PharmaEssentia USA resubmits BLA to the FDA, seeking approval for ropeginterferon alfa-2b-njft for polycythemia vera...
Israel assesses myocarditis cases linked to Pfizer-BioNTech Covid-19 vaccine
The Israel Health Ministry is examining a small number of cases related to inflammation of the heart muscle in individuals inoculated with Pfizer and BioNtech’s Covid-19 vaccine.
A segment of Covid-19 survivors face possible long-term complications
There is growing evidence that about 10% of people with Covid-19 will go on to experience 'long Covid', where symptoms such as fatigue, shortness of breath, fevers, gastrointestinal issues, sleep disorders, 'brain fog', anxiety, post-traumatic...
Heart Disease Deaths on the Rise in Young Women
As February is American Heart Month in the US, GlobalData epidemiologists are highlighting findings from a nationwide study on premature heart disease and cancer-related deaths in young women, published mid-February in the 'European Heart Journal...
Humacyte agrees SPAC merger to go public with bioengineered tissue tech
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC).
US judge orders BMS, Sanofi to pay $834m for illegal marketing of Plavix
US Judge Dean Ochiai has ordered Bristol-Myers Squibb (BMS) and Sanofi to pay over $834m to the state of Hawaii for illegally marketing their blood-thinning drug Plavix.
China approves AstraZeneca’s Forxiga for heart failure
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
